Drug
Pacritinib clinical trials
Also written SB1518 and Vonjo.
- studies test it
- 49
- open now
- 18
- in phase 3
- 3
- first study started
- 2008
Keep track of what changes. Save the pacritinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2026 (9)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 24
- Phase 2
- 31
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 31
CTI BioPharma (10) · S*BIO (4) · Washington University School of Medicine (4) · National Cancer Institute (NCI) (3) · University of Michigan Rogel Cancer Center (3) · M.D. Anderson Cancer Center (3) · Swedish Orphan Biovitrum (2) · University of Washington (2)
Often tested with
Tested in the same studies.
Azacitidine (4) · Decitabine (3) · Ruxolitinib (2) · Sirolimus (1) · Rifampin (1) · Clarithromycin (1) · Venetoclax (1) · Selinexor (1)
Studies
Open first, then newest update. How each study uses pacritinib is read from its arms, and is right about nine times in ten.
Testing it · 49
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingPhase 1/2National Cancer Institute (NCI)NCT06303193Written as pacritinib
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingPhase 1Roswell Park Cancer InstituteNCT07679334Written as Pacritinib
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)RecruitingPhase 2Swedish Orphan BiovitrumNCT06782373Written as Pacritinib
- Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT06052618Written as Pacritinib
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 1City of Hope Medical CenterNCT06675123Written as Pacritinib
- Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaRecruitingPhase 2Grupo Español de Enfermedades Mieloproliferativas Crónicas PH NegativasNCT07394153Written as Pacritinib
- Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05531786Written as Pacritinib
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT04282187Written as Pacritinib
- Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling InhibitorsRecruitingPhase 2Medical College of WisconsinNCT07226713Written as Pacritinib
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT07148947Written as Pacritinib
- Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaRecruitingPhase 2TheradexNCT07033598Written as Pacritinib
- Pacritinib in CMMLRecruitingPhase 1/2Douglas TremblayNCT06159491Written as Pacritinib
- Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeRecruitingPhase 1Washington University School of MedicineNCT06538181Written as Pacritinib
- Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingEarly Phase 1University of Kansas Medical CenterNCT06414681Written as Pacritinib
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingPhase 2John MascarenhasNCT07447817Written as Pacritinib
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT04858256Written as Pacritinib
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingPhase 2Shayna Sarosiek, MDNCT06986174Written as Pacritinib
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingPhase 1Fox Chase Cancer CenterNCT06218628Written as pacritinib
- Pacritinib With Aza for Upfront Myelodysplastic SyndromeWithdrawnPhase 1/2Thomas Jefferson UniversityNCT07387354Written as Pacritinib
- Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung AdenocarcinomaTerminatedPhase 1/2The University of Texas Health Science Center at San AntonioNCT06516887Written as pacritinib
See all 49 studies that test pacritinib →
Given in every arm · 3 — pacritinib is usual care beside what is tested
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Pacritinib
- Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 MutationsCompletedPhase 1Bhavana BhatnagarNCT02323607Written as Pacritinib
- Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AMLTerminatedPhase 2Weill Medical College of Cornell UniversityNCT02532010Written as Pacritinib
Codes
What other systems call pacritinib · ClinicalTrials.gg INT005890
- MeSH (NLM) C561234pacritinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G22N65IL3OPACRITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2595243One source FDA
- Wikidata Q3888693pacritinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78837PacritinibOne source FDA
- DrugBank DB11697One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561234 | pacritinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G22N65IL3O | PACRITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2595243 | — | One source FDA |
| Wikidata | Q3888693 | pacritinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78837 | Pacritinib | One source FDA |
| DrugBank | DB11697 | — | One source Wikidata |
Also registered as pacritinib citrate (UNII VJ2PH4NXX7 · RxNorm 2595242).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.